B
Eli Lilly and Company
LLY
NYSE
$329.89 $8.342.59% Volume2,622,532 10/04/2022 4:00PM Eastern Quotes delayed
Recommendation
Prev Close
Avg Vol (90D)
Market Cap
Dividend & Yield
52-Week Range
P/E (TTM)
EPS (TTM)
B
Buy 8/5/2022Downgrade
Eli Lilly and Company (LLY) was downgraded to B- from B on 8/5/2022 due to a significant decline in the growth index, valuation index and solvency index. Operating cash flow declined 67.16% from $2.5B to $820.7M, earnings per share declined from $2.1 to $1.05, and EBIT declined 34.48% from $2.66B to $1.74B.
B
Buy 4/29/2022Downgrade
Eli Lilly and Company (LLY) was downgraded to B from B+ on 4/29/2022 due to a noticeable decline in the growth index and total return index. Total revenue declined 2.37% from $8B to $7.81B.
B
Buy 4/18/2022Upgraded
Eli Lilly and Company (LLY) was upgraded to B+ from B on 4/18/2022 due to an increase in the total return index.
B
Buy 3/31/2022Downgrade
Eli Lilly and Company (LLY) was downgraded to B from B+ on 3/31/2022 due to a decline in the valuation index, dividend index and volatility index.
B
Buy 3/15/2022Upgraded
Eli Lilly and Company (LLY) was upgraded to B+ from B on 3/15/2022 due to a noticeable increase in the total return index, solvency index and growth index. Earnings per share increased from $1.22 to $1.8943, operating cash flow increased 32.2% from $1.63B to $2.16B, and total revenue increased 18.12% from $6.77B to $8B.
B
Buy 9/24/2021Downgrade
Eli Lilly and Company (LLY) was downgraded to B from B+ on 9/24/2021 due to a decline in the total return index.
B
Buy 9/9/2021Upgraded
Eli Lilly and Company (LLY) was upgraded to B+ from B on 9/9/2021 due to a large increase in the growth index, total return index and volatility index. EBIT increased 10.51% from $1.74B to $1.92B, operating cash flow increased 4.6% from $1.7B to $1.78B, and earnings per share increased from $1.49 to $1.53.
B
Buy 2/3/2021Upgraded
Eli Lilly and Company (LLY) was upgraded to B from B- on 2/3/2021 due to a substantial increase in the total return index, volatility index and growth index.
B
Buy 11/27/2020Downgrade
Eli Lilly and Company (LLY) was downgraded to B- from B on 11/27/2020 due to a substantial decline in the valuation index, growth index and dividend index. Operating cash flow declined 27.6% from $2.5B to $1.81B, and earnings per share declined from $1.55 to $1.33.
B
Buy 10/29/2019Upgraded
Eli Lilly and Company (LLY) was upgraded to B from B- on 10/29/2019 due to a significant increase in the growth index, valuation index and solvency index. Operating cash flow increased 43.61% from $1.05B to $1.51B, and debt to equity declined from 5.73 to 4.56.
B
Buy 9/5/2019Downgrade
Eli Lilly and Company (LLY) was downgraded to B- from B on 9/5/2019 due to a significant decline in the growth index, total return index and volatility index. Earnings per share declined from $4.3103 to $1.44.
B
Buy 5/7/2019Upgraded
Eli Lilly and Company (LLY) was upgraded to B from C+ on 5/7/2019 due to a significant increase in the valuation index, growth index and efficiency index. Earnings per share increased from $1.1048 to $4.3103, and net income increased 277.03% from $1.13B to $4.24B.
C
Hold 5/1/2019Downgrade
Eli Lilly and Company (LLY) was downgraded to C+ from B- on 5/1/2019 due to a decline in the total return index and volatility index.
B
Buy 2/21/2019Upgraded
Eli Lilly and Company (LLY) was upgraded to B- from C on 2/21/2019 due to a substantial increase in the total return index, volatility index and valuation index.
C
Hold 4/30/2018Upgraded
Eli Lilly and Company (LLY) was upgraded to C from C- on 4/30/2018 due to a noticeable increase in the growth index, solvency index and valuation index. Earnings per share increased from -$1.5764 to $1.16, debt to equity declined from 1.18 to 0.81, and EBIT increased 13.23% from $1.28B to $1.45B.
C
Hold 3/7/2018Downgrade
Eli Lilly and Company (LLY) was downgraded to C- from C on 3/7/2018 due to a substantial decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.5274 to -$1.5764, net income declined 398.22% from $555.6M to -$1.66B, and total capital declined 10.9% from $28.49B to $25.39B.
C
Hold 2/7/2018Downgrade
Eli Lilly and Company (LLY) was downgraded to C from C+ on 2/7/2018 due to a noticeable decline in the volatility index and total return index.
C
Hold 12/15/2017Downgrade
Eli Lilly and Company (LLY) was downgraded to C+ from B- on 12/15/2017 due to a decline in the volatility index, valuation index and dividend index.
B
Buy 11/30/2017Upgraded
Eli Lilly and Company (LLY) was upgraded to B- from C+ on 11/30/2017 due to an increase in the volatility index, total return index and valuation index.
C
Hold 10/27/2017Downgrade
Eli Lilly and Company (LLY) was downgraded to C+ from B- on 10/27/2017 due to a substantial decline in the growth index, valuation index and total return index. Earnings per share declined from $0.95 to $0.5274, EBIT declined 7.41% from $1.31B to $1.22B, and total revenue declined 2.86% from $5.82B to $5.66B.
B
Buy 7/31/2017Upgraded
Eli Lilly and Company (LLY) was upgraded to B- from C+ on 7/31/2017 due to a significant increase in the growth index, valuation index and solvency index. Earnings per share increased from -$0.1049 to $0.95, operating cash flow increased 385.76% from $339.9M to $1.65B, and the quick ratio increased from 0.78 to 0.92.
C
Hold 5/4/2017Downgrade
Eli Lilly and Company (LLY) was downgraded to C+ from B on 5/4/2017 due to a major decline in the growth index, valuation index and total return index. Earnings per share declined from $0.7271 to -$0.1049, operating cash flow declined 83.94% from $2.12B to $339.9M, and total revenue declined 9.24% from $5.76B to $5.23B.
B
Buy 4/26/2017Upgraded
Eli Lilly and Company (LLY) was upgraded to B from B- on 4/26/2017 due to an increase in the valuation index, total return index and dividend index.
B
Buy 4/11/2017Downgrade
Eli Lilly and Company (LLY) was downgraded to B- from B on 4/11/2017 due to a decline in the volatility index, valuation index and dividend index.
B
Buy 3/22/2017Upgraded
Eli Lilly and Company (LLY) was upgraded to B from B- on 3/22/2017 due to a noticeable increase in the total return index, volatility index and valuation index.
B
Buy 7/29/2016Upgraded
Eli Lilly and Company (LLY) was upgraded to B- from C+ on 7/29/2016 due to a substantial increase in the growth index and efficiency index. Operating cash flow increased 528.82% from -$326.9M to $1.4B, earnings per share increased from $0.41 to $0.7069, and net income increased 69.89% from $440.1M to $747.7M.
C
Hold 3/21/2016Downgrade
Eli Lilly and Company (LLY) was downgraded to C+ from B- on 3/21/2016 due to a noticeable decline in the volatility index, growth index and total return index. Earnings per share declined from $0.75 to $0.4492, EBIT declined 27.43% from $1.02B to $743.8M, and operating cash flow declined 27.19% from $1.1B to $804.3M.
B
Buy 2/4/2016Downgrade
Eli Lilly and Company (LLY) was downgraded to B- from B on 2/4/2016 due to a decline in the volatility index.
B
Buy 1/8/2016Upgraded
Eli Lilly and Company (LLY) was upgraded to B from B- on 1/8/2016 due to an increase in the valuation index.
B
Buy 12/4/2015Downgrade
Eli Lilly and Company (LLY) was downgraded to B- from B on 12/4/2015 due to a noticeable decline in the total return index, valuation index and dividend index.
B
Buy 11/3/2015Upgraded
Eli Lilly and Company (LLY) was upgraded to B from B- on 11/3/2015 due to a noticeable increase in the valuation index, growth index and dividend index. Earnings per share increased from $0.56 to $0.75, operating cash flow increased 16.46% from $948.6M to $1.1B, and EBIT increased 0.11% from $1.02B to $1.02B.
B
Buy 7/31/2015Upgraded
Eli Lilly and Company (LLY) was upgraded to B- from C+ on 7/31/2015 due to a substantial increase in the total return index, volatility index and growth index. Earnings per share increased from $0.4976 to $0.56, EBIT increased 7.46% from $952.7M to $1.02B, and total revenue increased 7.19% from $4.64B to $4.98B.
C
Hold 5/21/2015Downgrade
Eli Lilly and Company (LLY) was downgraded to C+ from B- on 5/21/2015 due to a decline in the volatility index, total return index and valuation index.
B
Buy 4/13/2015Upgraded
Eli Lilly and Company (LLY) was upgraded to B- from C+ on 4/13/2015 due to an increase in the volatility index, valuation index and dividend index.
C
Hold 3/27/2015Downgrade
Eli Lilly and Company (LLY) was downgraded to C+ from B- on 3/27/2015 due to a noticeable decline in the valuation index, total return index and solvency index. Debt to equity increased from 0.32 to 0.53, and the quick ratio declined from 1.11 to 0.77.
B
Buy 11/19/2014Downgrade
Eli Lilly and Company (LLY) was downgraded to B- from B on 11/19/2014 due to a noticeable decline in the growth index, valuation index and dividend index. Earnings per share declined from $0.68 to $0.468, EBIT declined 21.8% from $886.6M to $693.3M, and total revenue declined 1.22% from $4.94B to $4.88B.
B
Buy 10/24/2014Downgrade
Eli Lilly and Company (LLY) was downgraded to B from B+ on 10/24/2014 due to a decline in the total return index and volatility index.
B
Buy 10/9/2014Upgraded
Eli Lilly and Company (LLY) was upgraded to B+ from B on 10/9/2014 due to an increase in the valuation index and dividend index.
B
Buy 9/24/2014Downgrade
Eli Lilly and Company (LLY) was downgraded to B from B+ on 9/24/2014 due to a decline in the valuation index, solvency index and dividend index. The quick ratio declined from 1.35 to 1.2, and debt to equity increased from 0.29 to 0.3.
B
Buy 4/30/2014Downgrade
Eli Lilly and Company (LLY) was downgraded to B+ from A on 4/30/2014 due to a large decline in the growth index and valuation index. Operating cash flow declined 84.23% from $1.73B to $272.3M, total revenue declined 19.38% from $5.81B to $4.68B, and EBIT declined 12.8% from $993.3M to $866.2M.
A
Buy 3/14/2014Upgraded
Eli Lilly and Company (LLY) was upgraded to A from A- on 3/14/2014 due to a noticeable increase in the volatility index and total return index.
Weiss Ratings